Secure CheckoutPersonal information is secured with SSL technology.
Free ShippingFree global shipping
No minimum order.
Equitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers. With detailed country-by country analysis of policy and regulation, the Work compares and contrasts national healthcare systems to support researchers and practitioners identify optimal healthcare policy solutions. The Work incorporates chapters on global regulatory changes, health technology assessment guidelines, and competitive effectiveness research recommendations from international bodies such as the OECD or the EU. Novel policies such as horizon scanning, managed-entry agreement and post-launch monitoring are considered in detail. The Work also thoroughly reviews novel pharmaceuticals with particular research interest, including cancer drugs, orphan medicines, Hep C, and personalized medicines.
- Evaluates impact and efficacy of current access policies and pricing regulation of high-cost drugs
- Incorporates existing guidelines and recommendations by international organizations
- Compares and contrasts how different countries fund and police high-cost drug access
- Explores novel and emergent policies, including managed entry agreement, analysis of real world data and differential pricing
- Reviews novel pharmaceuticals of current research interest
Pharmacoeconomics, health economics, pharmacy, public health and health administration professionals. Policymakers and funding bodies. Pharmaceutical research and insurance staff working across pricing, market access, policy and marketing. Some graduate and 1st year PhD students studying pharmacoeconomics, pharmacy and health economics
1. Access to High Cost Medicines: An Overview
2. Health Technology Assessment
3. High-Cost Medicines in England
4. Managed Entry Agreements and High Cost Medicines (European Perspective)
5. Setting a Public Health Agenda to Support Access to High-Cost Medicines
6. Human Rights and Intellectual Property for Universal Access to New Essential Medicines
7. Access to High Price Medicines in Portugal
8. Improving Access to High-Cost Medicines in Low Income Countries in Africa: Creating a Functioning Pharmaceutical System in Uganda
9. Equitable Access to Biosimilars: An Overview
10. Access to High-Cost Medicines in Europe
11. Access to High-Cost Medicines in Australia
12. Access to High-Cost Medicines in New Zealand
13. Access to High-Cost Medicines in Wales
- No. of pages:
- © Academic Press 2018
- 21st February 2018
- Academic Press
- Paperback ISBN:
- eBook ISBN:
Professor Zaheer-Ud-Din Babar is Professor in Medicines and Healthcare and the Director of Centre of Pharmaceutical Policy and Practice Research at the University of Huddersfield, United Kingdom. He is globally known for his work in pharmaceutical policy and practice, including quality use of medicines, clinical pharmacy practice, access to medicines and issues related to pharmacoeconomics. He has published in high impact journals such as PLoS Medicine and the Lancet and has acted as a consultant for World Health Organization, Royal Pharmaceutical Society, Health Action International, International Union Against Tuberculosis and Lung Disease, World Bank, European Union, International Pharmaceutical Federation (FIP) and for the Pharmaceutical Management Agency of New Zealand. His edited work includes "Economic evaluation of pharmacy services", “Pharmaceutical prices in the 21st century”, “Pharmaceutical policies in countries with developing healthcare systems ", “Global Pharmaceutical Policy”, “Pharmacy Practice Research Methods” and “Encyclopedia of Pharmacy Practice and Clinical Pharmacy”. Published by Elsevier and Adis/Springer, the work is used in curriculum design, policy development and for referral all around the globe. Professor Babar is also the Editor-in-Chief of BMC Journal of Pharmaceutical Policy and Practice and can be contacted at firstname.lastname@example.org
Professor in Medicines and Healthcare and Director, Centre of Pharmaceutical Policy and Practice Research, University of Huddersfield, UK
"Equitable Access to High-Cost Pharmaceuticals forms an all-inclusive source of knowledge for understanding the issues surrounding access to and cost of new medicines by merging theory with practice, providing a comprehensive outlook on pharmaceutical policy and regulation challenges." --Aris Angelis, The London School of Economics and Political Science
Elsevier.com visitor survey
We are always looking for ways to improve customer experience on Elsevier.com.
We would like to ask you for a moment of your time to fill in a short questionnaire, at the end of your visit.
If you decide to participate, a new browser tab will open so you can complete the survey after you have completed your visit to this website.
Thanks in advance for your time.